Teriparatide for idiopathic osteoporosis in premenopausal women: A pilot study

Context: Premenopausal women with idiopathic osteoporosis (IOP) have abnormal cortical and trabecular bone microarchitecture. Objective: The purpose of this study was to test the hypotheses that teriparatide increases bone mineral density (BMD) and bone formation and improves trabecular microarchitecture and stiffness in women with IOP. Design: This was an open-label pilot study. Setting: The setting was a tertiary care referral center. Patients: Participants were 21 premenopausal women with unexplained fragility fractures or low BMD. Intervention: Teriparatide was administered at 20 μg daily for 18 to 24 months. Main Outcome Measures: The primary endpoint was within-subject percent change in lumbar spine BMD. Secondary endpoints included percent change in hip and forearm BMD, transiliac biopsy parameters (trabecular bone volume, microarchitecture, stiffness, and adipocytes), serum N-terminal propeptide of procollagen type 1 (P1NP), and C-telopeptide. Results: BMD increased at the spine (10.8 ± 8.3% [SD])...